Thyrocare Technologies has announced the launch of the GLP-1 Health Check, a set of packages with up to 81 tests designed to monitor health parameters before, during, and after GLP-1 therapy. The packages are priced from ₹2,799 and are available across India. Thyrocare stated that the offering aims to support individuals and clinicians with diagnostic insights through all stages of treatment.
GLP-1, or Glucagon-Like Peptide-1, is a natural hormone involved in regulating blood sugar, controlling appetite, and slowing digestion. GLP-1 agonist medications, which mimic this hormone, are being prescribed for obesity and type 2 diabetes. Their increasing use for weight loss has generated public interest and medical caution, with clinicians highlighting the requirement for continuous monitoring to track treatment safety and progress.
Thyrocare noted that the GLP-1 packages have been developed to help individuals establish a health baseline before therapy and assess progress as treatment continues. Regular monitoring supports early detection of side effects, nutritional deficiencies, and changes in metabolic functions, enabling safe use of therapy under medical supervision.
The company stated that individuals with obesity or type 2 diabetes often experience insulin resistance, high blood sugar, cholesterol issues, fatty liver, and increased cardiovascular risk. With this in view, Thyrocare said it has curated GLP-1 packages in partnership with clinicians.
The packages include tests to monitor lipid profile, fasting blood glucose, fasting insulin, HOMA insulin resistance index, liver function, and cardiac risk markers to assess how the medication is working. Kidney function testing is recommended before starting therapy and during the course of treatment to establish a baseline and detect side effects such as dehydration or electrolyte imbalance. Thyrocare added that reduced appetite from GLP-1 medicines may lead to nutritional deficiencies or anaemia, making regular testing of vitamin D, vitamin B12, and haemoglobin necessary. Some cases of GLP-1 therapy can involve pancreatitis and thyroid disorders, and therefore the packages include assessments for pancreatic health (amylase, lipase) and thyroid function (T3, T4, TSH).
All tests are included in a single package, which Thyrocare said enables comprehensive testing while undergoing GLP-1 therapy.
Commenting on the launch, Rahul Guha, MD and CEO, Thyrocare Technologies, said, “As GLP-1-based medicines become more widely used in India for weight management and diabetes, it’s important to accompany this trend with reliable diagnostic support. These therapies are powerful and effective when used responsibly, but they work best when combined with consistent monitoring. With this package, our goal is to make that process easier and more accessible for people across the country.”
Thyrocare stated that the packages support mapping of health trends and treatment progress over time, giving individuals and clinicians insights for the continued and informed use of GLP-1 therapies.
Dr Shehla Shaikh, MD (General Medicine), DM (Endocrinology), consulting endocrinologist at multiple hospitals, said, “As obesity emerges as a global health challenge, it is essential to pair weight-management GLP-1 therapy with structured medical monitoring, beginning with baseline screening and continuing with periodic reviews. These treatments are highly effective when supervised, and comprehensive testing helps ensure nutritional balance, organ health, and long-term safety.”
The packages can be booked through Thyrocare, Pharmeasy, and all partners. The company said that by making metabolic testing available at the stated price point, it aims to support preventive and precision healthcare for individuals managing diabetes, obesity, or metabolic health.